Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children

Vaccine

Volumn 30, Issue 26, 2012, Pages 3975-3981

  Karron, Ruth A ^a   Thumar, Bhagvanji ^a   Schappell, Elizabeth ^a   Surman, Sonja ^b   Murphy, Brian R ^b   Collins, Peter L ^b   Schmidt, Alexander C ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Clinical trial; Live attenuated vaccine; Parainfluenza

Indexed keywords

ALANINE AMINOTRANSFERASE; CHIMERIC BOVINE HUMAN PARAINFLUENZA VIRUS TYPE 3 VACCINE; COMPLEMENTARY DNA; LIVE VACCINE; PARAINFLUENZA VACCINE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; BOCAVIRUS; CHILD; CHIMERA; CLINICAL TRIAL; CORONAVIRUS; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN METAPNEUMOVIRUS; IMMUNOGENICITY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; VACCINATION; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS SHEDDING;

ADMINISTRATION, INTRANASAL; ADULT; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 3, HUMAN; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRUS REPLICATION; VIRUS SHEDDING;

EID: 84861192073     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.022     Document Type: Article

References (37)

1. Chanock R.M., Parrott R.H. Acute respiratory disease in infancy and childhood: present understanding and prospects for prevention. Pediatrics 1965, 36:21-39.
2. Glezen W.P., Denny F.W. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973, 288:498-505.
3. Counihan M.E., Shay D.K., Holman R.C., Lowther S.A., Anderson L.J. Human parainfluenza virus-associated hospitalizations among children less than five years of age in the United States. Pediatr Infect Dis J 2001, 20(7):646-653.
4. Weinberg G.A., Hall C.B., Iwane M.K., Poehling K.A., Edwards K.M., Griffin M.R., et al. Parainfluenza virus infection of young children: burden of hospitalization and seasonal patterns of infection 2004, Society for Pediatric Research, San Francisco, CA, p. 1824.
5. Weinberg G.A. Parainfluenza viruses: an underappreciated cause of pediatric respiratory morbidity. Pediatr Infect Dis J 2006, 25(5):447-448.
6. Weinberg G.A., Hall C.B., Iwane M.K., Poehling K.A., Edwards K.M., Griffin M.R., et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009, 154(5):694-699.
7. Glezen W.P., Frank A.L., Taber L.H., Kasel J.A. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984, 150(6):851-857.
8. Karron R.A., O'Brien K.L., Froehlich J.L., Brown V.A. Molecular epidemiology of a parainfluenza type 3 virus outbreak on a pediatric ward. J Infect Dis 1993, 167(6):1441-1445.
9. Reed G., Jewett P.H., Thompson J., Tollefson S., Wright P.F. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis 1997, 175(4):807-813.
10. Karron R.A., Makhene M., Gay K., Wilson M.H., Clements M.L., Murphy B.R. Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in 2-to-6-month-old infants. Pediatr Infect Dis J 1996, 15:650-654.
11. Karron R.A., Belshe R.B., Wright P.F., Thumar B., Burns B., Newman F., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003, 22(5):394-405.
12. Karron R.A., Casey R., Thumar B., Surman S., Murphy B.R., Collins P.L., et al. The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well-tolerated, infectious, and immunogenic in infants and young children. Pediatr Infect Dis J 2011, 30(10):e186-e189.
13. Smith C.B., Purcell R.H., Bellanti J.A., Chanock R.M. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 1966, 275(21):1145-1152.
14. Tremonti L.P., Lin J.L., Jackson G.G. Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2. J Immunol 1968, 101:572-577.
15. Clements M.L., Makhene M.K., Karron R.A., Murphy B.R., Steinhoff M.C., Subbarao K., et al. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. J Infect Dis 1996, 173:44-51.
16. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe J.E., Boyce T.G., et al. Evaluation of a live cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000, 182(5):1331-1342.
17. Homa F.L., Brideau R.J., Lehman D.J., Thomsen D.R., Olmsted R.A., Wathen M.W. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3. J Gen Virol 1993, 74:1995-1999.
18. Spriggs M.K., Murphy B.R., Prince G.A., Olmsted R.A., Collins P.L. Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunity. J Virol 1987, 61:3416-3423.
19. Ray R., Glaze B.J., Moldoveanu Z., Compans R.W. Intranasal immunization of hamsters with envelope glycoproteins of human parainfluenza virus type 3. J Infect Dis 1988, 157(4):648-654.
20. Ambrose M.W., Wyde P.R., Ewasyshyn M., Bonneau A.M., Caplan B., Meyer H.L., et al. Evaluation of the immunogenicity and protective efficacy of a candidate parainfluenza virus type 3 subunit vaccine in cotton rats. Vaccine 1991, 9(7):505-511.
21. Skiadopoulos M.H., Schmidt A.C., Riggs J.M., Surman S.R., Elkins W.R., St Claire M., et al. Determinants of the host range restriction of replication of bovine parainfluenza virus type 3 in rhesus monkeys are polygenic. J Virol 2003, 77(2):1141-1148.
22. Karron R.A., Wright P.F., Hall S.L., Makhene M., Thompson J., Burns B.A., et al. A live attenuated bovine parainfluenza type 3 virus vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995, 171:1107-1114.
23. Sato M., Wright P.F. Current status of vaccines for parainfluenza virus infections. Pediatr Infect Dis J 2008, 27(10 Suppl.):S123-S125.
24. Bailly J.E., McAuliffe J.M., Durbin A.P., Elkins W.R., Collins P.L., Murphy B.R. A recombinant human parainfluenza virus type 3 (PIV3) in which the nucleocapsid N protein has been replaced by that of bovine PIV3 is attenuated in primates. J Virol 2000, 74(7):3188-3195.
25. Bailly J.E., McAuliffe J.M., Skiadopoulos M.H., Collins P.L., Murphy B.R. Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates. Virus Genes 2000, 20(2):173-182.
26. Schmidt A.C., McAuliffe J.M., Huang A., Surman S.R., Bailly J.E., Elkins W.R., et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 2000, 74(19):8922-8929.
27. Surman S.R., Collins P.L., Murphy B.R., Skiadopoulos M.H. An improved method for the recovery of recombinant paramyxovirus vaccine candidates suitable for use in human clinical trials. J Virol Methods 2007, 141(1):30-33.
28. Clements M.L., Belshe R.B., King J., Newman F., Westblom T.U., Tierney E.L., et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991, 29:1175-1182.
29. Coelingh K.L.V., Winter C.C., Murphy B.R. Conserved epitopes of the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 1986, 60:90-96.
30. van Wyke Coelingh K.L., Winter C.C., Tierney E.L., Hall S.L., London W.T., Kim H.W., et al. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus. J Virol 1990, 64(8):3833-3843.
31. Valarcher J.F., Furze J., Wyld S., Cook R., Conzelmann K.K., Taylor G. Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J Virol 2003, 77(15):8426-8439.
32. Murphy B.R., Collins P.L. Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest 2002, 110(1):21-27.
33. Ambrose C.S., Yi T., Falloon J. An integrated, multistudy analysis of the safety of Ann Arbor strain live attenuated influenza vaccine in children aged 2-17 years. Influenza Other Respir Viruses 2011.
34. Karron R.A., Wright P.F., Newman F.K., Makhene M., Thompson J., Samorodin R., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995, 172:1445-1450.
35. Belshe R.B., Newman F.K., Tsai T.F., Karron R.A., Reisinger K., Roberton D., et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004, 189(3):462-470.
36. Schmidt A.C., Wenzke D.R., McAuliffe J.M., St Claire M., Elkins W.R., Murphy B.R., et al. Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol 2002, 76(3):1089-1099.
37. Gomez M., Mufson M.A., Dubovsky F., Knightly C., Zeng W., Losonsky G. Phase-I study MEDI-534: of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 2009, 28(7):655-658.